1. Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
   Lilan Yi et al, 2019, International Journal of Cancer CrossRef
2. Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
   Takahiro Uchida et al, 2019, Thoracic Cancer CrossRef
3. The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy
   Yuki Shinno et al, 2020, JTO Clinical and Research Reports CrossRef
4. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring
   Satoshi Noda et al, 2022, Biological and Pharmaceutical Bulletin CrossRef
5. Pneumonitis following Pembrolizumab and radiation therapy in a patient with lung cancer and rib metastasis
   Saki Nakajima et al, 2020, Medicine: Case Reports and Study Protocols CrossRef
6. Lung spindle cell carcinoma harbouring a constitutively active epidermal growth factor receptor mutation
   Hiroaki Ikushima et al, 2019, Respirology Case Reports CrossRef
7. Life‐threatening pneumonitis after first‐line treatment with osimertinib for primary T790M mutated non‐small cell lung cancer
   Maik Häntschel et al, 2020, Thoracic Cancer CrossRef
8. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
   Andrew J. Piper-Vallillo et al, 2020, Journal of Clinical Oncology CrossRef
9. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
   Zheng-Hai Tang et al, 2018, Cancer Letters CrossRef
10. Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Daisy Chan et al, 2022, Cancers CrossRef
11. Multiple Primary Lung Cancers Containing Adenocarcinoma with EGFR Gene Mutation and Adenocarcinoma with Strong PD-L1 Positivity
    Yasuyuki Hayashi et al, 2018, Haigan CrossRef
12. An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring
    Kei Irie et al, 2018, Therapeutic Drug Monitoring CrossRef
13. Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review
    Wenyan Chen et al, 2023, Anti-Cancer Drugs CrossRef